拉西地平和氨氯地平治疗高血压的安全性比较  

Safty evaluation of lacidipiae and lacidipine in treating essential hypertension

作　　者：石蔚萍[1] 王利波[1] 

机构地区：[1]杭州师范学院医学院附属医院心血管内科,浙江杭州310015

出　　处：《杭州师范学院学报（医学版）》2006年第4期250-251,共2页Journal of Hangzhou Teachers College :Medical Edition

摘　　要：目的比较观察长效二氢吡啶类钙离子拮抗剂拉西地平及氨氯地平治疗轻、中度高血压的安全性。方法采用开放式、平行对照试验,共选取114例轻、中度原发性高血压患者,分别服用拉西地平片4mg,1次/日(61例)、氨氯地平片5mg,1次/日(53例),患者平均治疗6个月并随访。结果治疗后两组血压下降无显著性差异(P>0.05),而应用拉西地平组水肿发生率3.28%显著低于氨氯地平组的15.09%(P<0.05)。其余不良反应两组间无显著性差异(P>0.05)。结论拉西地平是一种具有良好的疗效和耐受性的理想降压药物。Objective To observe and compare the efficacy and safety of lacidipiae（ lae） and lacidipine on mild-to-moderate essential hypertension. Methods 114 cases with essential hypertension were randomly divided into 2 groups：the laeidipine group（n =61, oral- ly took lacidipine 4mg once per day） and the lacidipine group（n = 53, orally took laeidipine 5mg once per day）. The treatment had lasted for 6 months and all patients were followed up. Results Blood pressure in both group significantly reduced after treatment, however, there ,was no significant difference between these two groups. ly lower than that in the amlodipine group（ 3.28% vs15.09% , P 〈 0 05）.Conclusion Lacidpine is effective in treating mild-tomoderate essential hypertensiun and has less side effect.

关 键 词：拉西地平 氨氯地平 安全性 水肿 

分 类 号：R972.4[医药卫生—药品]